Background: Multifocal (MFBC)/multicentric (MCBC) breast cancer is being more recognized due to the improved imaging modalities and the greater orientation with this form of breast cancer, however, optimal surgical treatment, still poses a challenge. The standard surgical treatment is mastectomy, however, breast-conserving surgeries (BCS) may be appropriate in certain situations.
Methods: A total of 464 cases of MF/MCBC out of 4798 cases of breast cancer were retrospectively analyzed from the database of the Oncology Center, Mansoura University (OCMU), between January 2008 and December 2019.
Results: Radiologic involvement of multiple quadrants was reported in 27.9% by ultrasonography, 19% by mammography, and 59.1% by magnetic resonance imaging. BCS was performed in 32 cases (6.9%) while 432 cases underwent a mastectomy. Postoperative pathology revealed infiltration of other quadrants grossly in 23.5%, and under the microscope in 63.6% of the examined cases. Mean disease-free and overall survival were 95.5 and 164.6 months, respectively. When compared with MFBC, MCBC showed higher pathologic tumor size (p < 0.001), higher stages (p < 0.001), higher recurrence rates (p = 0.006), and lower DFS (P = 0.009) but with similar OS (P = 0.8).
Conclusion: Mastectomy is still the primary treatment option for MCBC with higher recurrence rates compared with MFBC. However, BCS for properly selected MFBC is considered oncologically safe, following the same rules of breast conservation for unifocal disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/BD-220066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Examination of immunohistochemical of the effects of flattened and unflattened radiotherapy beams in nude mice breast cancer xenografts.
Int J Radiat Biol
January 2025
Department of Neurosurgery, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
Purpose: The aim of this study was to investigate the radiobiological effects underlying the inhibition of breast cancer (BCa) following radiotherapy in nude mice models, and to evaluate the impact of changes in immunohistochemical parameters induced by FF and FFF beams.
Materials And Methods: The study included thirty-six adult nude mouse models, which were randomly assigned to five groups: control (G1), breast cancer (BCa) (G2), FF-400 MU/min (G3), FFF-1100 MU/min (G4), and FFF-1800 MU/min (G5). The control group received neither radiation nor treatment, while the BCa group had a cancer model without radiation.
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-The Phase III MECCA Trial.
J Clin Oncol
January 2025
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Purpose: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial.
Methods: Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled.
Purpose: In light of evolving evidence that some patients with node-positive estrogen receptor-positive (ER+) disease may receive less benefit from chemotherapy, this study reports 12-year outcomes of the C9741 trial overall, and by the sensitivity to endocrine therapy (SET2,3) test index, a biomarker measuring endocrine transcriptional activity, to identify patients most likely to benefit from dose-dense chemotherapy.
Methods: In all, 1,973 patients were randomly assigned to dose-dense versus conventional chemotherapy. Hazard ratios (HRs) for prognosis and for predictive interaction with chemotherapy schedule were estimated from Cox models of long-term disease-free survival (DFS) and overall survival (OS).
Cytotoxic Ruthenium(II)-diphosphine Complexes affect the Mitochondrial Respiration of Lung Cancer Cells.
Chembiochem
January 2025
Universidade Federal de São Carlos: Universidade Federal de Sao Carlos, Departament of Chemistry, 13565-905, São Carlos, BRAZIL.
In this work, we studied six Ruthenium(II)-diphosphine compounds containing different mercapto ligands (N-S), with general formula [Ru(N-S)(dppm)2]Cl (dppm = 1,1-bis(diphenylphosphino)methane). These compounds were characterized by several techniques (NMR [1H, 31P(1H), and 13C], HRMS, IR, UV-Vis and XRD) and their purity confirmed by elemental analysis. DLS experiments revealed low diameters and polydispersity indexes, and positive log P values in n-octanol/PBS indicated their preference for the organic phase.
View Article and Find Full Text PDFSustainable Synthesis of Nitrogen-Embedded CuS Quantum Dots for In Vitro and In Vivo Breast Cancer Management.
ACS Appl Bio Mater
January 2025
Interdisciplinary Nanotechnology Centre (INC), Z. H. College of Engineering and Technology, Aligarh Muslim University, AMU, Aligarh 202002, Uttar Pradesh, India.
The burgeoning field of nanomedicine is exploring quantum dots for cancer theranostics. In recent years, chemically engineered copper sulfide (CuS) quantum dots (QDs) have emerged as a multifunctional platform for fluorescence-based sensors with prominent applications in imaging and chemodynamic therapy of tumor cells. The present study demonstrates the sustainable synthesis of nitrogen-embedded copper sulfide (N@CuS) quantum dots for the first time and unveils their potential application in in vitro and in vivo breast cancer management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!